NetworkNewsBreaks – Scinai Immunotherapeutics Lt
Post# of 88
(Total Views: 144)
Posted On: 12/12/2023 3:23:47 PM
NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports on Preclinical Results from Psoriatic Human Skin Trial
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, has announced successful preclinical trial results of its innovative anti–IL–17 VHH antibody (“NanoAb”). The trial evaluated Scinai’s NanoAbs as a local treatment for the large and underserved population of mild to moderate plaque psoriasis. The study was conducted by Genoskin, a French biotechnology company. According to the announcement, Genoskin’s human skin models were induced for expression of plaque psoriasis symptoms, thereby enabling ex–vivo examination of the therapeutic effects of drugs targeting underlying mechanisms in the pathogenesis of plaque psoriasis, specifically the IL-17 family of pro-inflammatory cytokines. The results exhibited the potential for Scinai’s anti-IL-17 NanoAbs to improve psoriatic skin lesions. The company noted that the results confirm and build upon previous studies and reports. “These positive results mark a significant step forward in the development of a novel treatment for the undertreated segment of mild and moderate plaque psoriatic patients,” said Scinai Immunotherapeutics chief scientist Dr. Tamar Ben-Yedidia in the press release. “To date, most of the innovation related to treatment of autoimmune diseases focused on drugs aimed at the more severe cases of these diseases, leaving milder cases with generic topical drugs and phototherapy treatments. The mild psoriatic patients account for more than 50% of the plaque psoriatic patients, and while undertreated they are prone to disease deterioration and worsening of symptoms, mainly painful skin lesions. Scinai’s vision is to become the ‘Botox-like solution,’ providing a highly efficacious, specific and safe biologic for local treatment of plaque psoriasis lesions.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, has announced successful preclinical trial results of its innovative anti–IL–17 VHH antibody (“NanoAb”). The trial evaluated Scinai’s NanoAbs as a local treatment for the large and underserved population of mild to moderate plaque psoriasis. The study was conducted by Genoskin, a French biotechnology company. According to the announcement, Genoskin’s human skin models were induced for expression of plaque psoriasis symptoms, thereby enabling ex–vivo examination of the therapeutic effects of drugs targeting underlying mechanisms in the pathogenesis of plaque psoriasis, specifically the IL-17 family of pro-inflammatory cytokines. The results exhibited the potential for Scinai’s anti-IL-17 NanoAbs to improve psoriatic skin lesions. The company noted that the results confirm and build upon previous studies and reports. “These positive results mark a significant step forward in the development of a novel treatment for the undertreated segment of mild and moderate plaque psoriatic patients,” said Scinai Immunotherapeutics chief scientist Dr. Tamar Ben-Yedidia in the press release. “To date, most of the innovation related to treatment of autoimmune diseases focused on drugs aimed at the more severe cases of these diseases, leaving milder cases with generic topical drugs and phototherapy treatments. The mild psoriatic patients account for more than 50% of the plaque psoriatic patients, and while undertreated they are prone to disease deterioration and worsening of symptoms, mainly painful skin lesions. Scinai’s vision is to become the ‘Botox-like solution,’ providing a highly efficacious, specific and safe biologic for local treatment of plaque psoriasis lesions.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)